Immuneering Corporation (NASDAQ:IMRX) Receives $16.50 Consensus Target Price from Brokerages

Shares of Immuneering Corporation (NASDAQ:IMRX) have been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $16.50.

Several brokerages have recently commented on IMRX. Chardan Capital restated a “buy” rating and set a $20.00 price target on shares of Immuneering in a research note on Thursday, November 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a research report on Monday, December 8th. Leerink Partners initiated coverage on Immuneering in a research report on Friday, October 31st. They issued an “outperform” rating and a $15.00 target price on the stock. Needham & Company LLC upped their target price on Immuneering from $8.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, September 15th. Finally, Oppenheimer boosted their target price on Immuneering from $21.00 to $30.00 and gave the company an “outperform” rating in a research note on Thursday, September 25th.

Immuneering Price Performance

Immuneering stock opened at $5.78 on Friday. The business has a 50 day simple moving average of $6.50 and a 200-day simple moving average of $5.24. Immuneering has a 12 month low of $1.10 and a 12 month high of $10.08. The stock has a market capitalization of $373.21 million, a PE ratio of -3.25 and a beta of 0.46.

Immuneering (NASDAQ:IMRX) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). As a group, equities research analysts anticipate that Immuneering will post -1.86 EPS for the current year.

Insider Activity at Immuneering

In other news, Director Peter Feinberg acquired 7,500 shares of Immuneering stock in a transaction that occurred on Friday, October 3rd. The stock was bought at an average price of $6.67 per share, for a total transaction of $50,025.00. Following the completion of the transaction, the director owned 156,766 shares in the company, valued at $1,045,629.22. The trade was a 5.02% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last three months, insiders acquired 20,800 shares of company stock valued at $143,754. 22.90% of the stock is currently owned by company insiders.

Institutional Trading of Immuneering

A number of institutional investors have recently modified their holdings of the company. Jane Street Group LLC purchased a new position in shares of Immuneering in the 1st quarter valued at about $32,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Immuneering during the 3rd quarter worth approximately $35,000. Future Financial Wealth Managment LLC acquired a new stake in Immuneering during the 3rd quarter valued at $35,000. Kingsview Wealth Management LLC purchased a new position in Immuneering during the second quarter worth approximately $47,000. Finally, Mercer Global Advisors Inc. ADV purchased a new position in Immuneering in the 3rd quarter valued at about $70,000. 67.65% of the stock is currently owned by institutional investors.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.